FDA Releases Guidance for Classifying CNS Clinical Trial Assessments

The FDA has issued new guidance requiring that assessments in Central Nervous System (CNS) clinical trials be classified as either in-person or remote before patient enrollment. This aims to maintain the integrity of primary endpoints in hybrid CNS programs, necessitating clear classification and statistical analysis planning from the outset to prevent issues during regulatory review.